Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Immunol.

Sec. Cancer Immunity and Immunotherapy

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1663396

characteristics of tertiary lymphoid structures in prostate cancer and the impact of neoadjuvant therapy on their formation and maturation

Provisionally accepted
  • 1Department of Urology, West China Hospital, Sichuan University, Chengdu, China
  • 2West China Hospital of Sichuan University State Key Laboratory of Biotherapy, Chengdu, China

The final, formatted version of the article will be published soon.

PURPOSE This study investigates the characteristics and prognostic significance of tertiary lymphoid structures (TLS) in prostate cancer (PCa), and explores the impact of neoadjuvant hormone therapy (NHT) on TLS formation and maturation. MATERIALS AND METHODS TLS features and immune infiltration were assessed in PCa cohorts using H&E and multiplex immunohistochemistry (mIHC) for Ki67, panCK, CD21, CD4, CD8, and CD20. Public datasets compared TLS signatures between NHT-treated and NHT-naïve patients, and between paired pre-/post-NHT samples. An orthotopic immunocompetent PCa mouse model was generated using organoids and CRISPR-Cas9. Flow cytometry evaluated immune infiltration in bicalutamide-treated mice, and anti-PD1 was combined with degarelix/bicalutamide in preclinical mouse model. RESULTS TLS were detected in 93% of NHT-naïve PCa tissues, predominantly within tumors. Mature TLS, secondary follicle-like TLS (SFL-TLS), and higher intra-tumoral TLS density correlated with prolonged progression-free survival (PFS). NHT-treated patients exhibited elevated TLS maturity, density, and immune infiltration (CD4+, CD8+, CD20+, CD21+ cells). Matched biopsies confirmed NHT enhanced TLS detection, maturation, and intra-TLS CD8+ T cell infiltration. Transcriptomics revealed upregulated CD4, CD8, CD20, and FOXP3 post-NHT. In mice, androgen deprivation therapy (ADT) increased immune infiltration, and anti-PD1/ADT combination improved tumor response. CONCLUSION Our findings demonstrate that TLS serve as a favorable prognostic biomarker in prostate cancer. NHT enhances TLS formation, maturation, and immune cell infiltration, suggesting a synergistic role for androgen deprivation in shaping the tumor immune microenvironment. The improved anti-tumor response with combined anti-PD1 and ADT highlights the potential of immunotherapy-endocrine therapy combinations as a promising treatment strategy for PCa.

Keywords: prostate cancer, Organoid, Tertiary lymphatic structures (TLSs), Neoadjuvant hormonal therapy (NHT), Immunotherapy

Received: 10 Jul 2025; Accepted: 09 Oct 2025.

Copyright: © 2025 Liu, Yu, Zhou, Yang, Yan, Liu, Ma, Liu, Wang, Zhao and Dong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Xianding Wang, xiandingwang@scu.edu.cn
Chengjian Zhao, chjianzhao@scu.edu.cn
Qiang Dong, dongqiang@scu.edu.cn

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.